

16 May 2024

Scancell Holdings plc
("Scancell" or the "Company")

Scancell to present at the Sachs 10th Annual Oncology Innovation Forum

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce that its Chief Financial Officer, Sath Nirmalanathan, will be presenting, and taking part in a panel discussion, at the Sachs 10th Annual Oncology Innovation Forum taking place on the 31st May 2024, at the beginning of the ASCO meeting.

Sath will be participating in the "Advanced Immunotherapies Panel: Cell Therapies & Cancer Vaccines", alongside other companies including AstraZeneca, BTIG and Lumanity. The panel will discuss the current and future role of cell therapies and cancer vaccines and take place from 11:40am - 12:30pm CDT.

Sath has also been invited to give a company presentation, taking place from 1:20pm - 1:40pm CDT at Track B, Sinclair Ballroom, where he will discuss the ongoing Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma and early data from the ongoing Phase 1/2 ModiFY trial with patients receiving Modi-1 as a monotherapy in a range of hard-to-treat solid tumours, which has shown good T cell responses, safety and tolerability.

Sath Nirmalanathan, Chief Financial Officer and Director of Scancell, said: "I am pleased to be invited to participate in both the panel discussion and to present details from our ongoing Phase 2 SCOPE trial and MofiFY study at this esteemed Forum. The program is focused on the latest innovation in IO targets and modalities, and I am also looking forward to highlighting the potential of our proprietary antibody technology platform and our innovative cancer vaccines, and to showcase the great work Scancell is making in this field."

If you would like to arrange a meeting at the Forum, please contact commercial.enquiries@scancell.co.uk.

-ENDS-

For further information, please contact:

Scancell Holdings plc

+44 (0) 20 3709 5700

Professor Lindy Durrant, CEO

Dr Jean-Michel Cosséry, Non-Executive Chairman

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7710 7600

Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)

Nick Harland (Corporate Broking)

WG Partners LLP (Joint Broker)

+44 (0) 20 3705 9330

David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope[®] and ImmunoBody[®] for vaccines and GlyMab[®] and AvidiMab[®] for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope[®] and ImmunoBody[®]) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab[®]) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab[®]).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSFMFIIESELI